Neko Health: Capital Raising

The leadership read

Neko Health's Series B commits the company to a commercial-scale rollout of its scanning infrastructure, not further platform development. At $260 million, the round is sized for site expansion, hardware fleet deployment, and the clinical and regulatory groundwork required to operate diagnostic-adjacent services across multiple jurisdictions. The company is no longer validating the technology; it is building the operational layer that converts scan volume into a defensible health-data business. This is one of twelve capital-raising signals we have tracked across the last 90 days, set against a backdrop the Tech.eu data makes legible: European health tech investment in 2025 concentrated heavily in later-stage rounds, with the UK alone absorbing €2.5 billion and Series B and beyond reflecting explicit bets on companies moving toward commercialisation. Comparable large-round activity includes Oura Health's $900 million raise and Isomorphic Labs' $600 million debut round. The consistent pattern is capital flowing to AI-enabled health platforms with hardware or biological-data moats rather than pure software plays. Companies reaching this stage of capital concentration in AI-enabled diagnostics and health-data infrastructure face rising demand for commercial leadership capable of multi-site clinic operations, regulatory affairs across EU and UK regimes post-divergence, and product management at the intersection of medical device compliance and consumer health experience. The market is moving toward operators who can close the distance between scan throughput and clinically meaningful data products at scale.